Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
321-340 of 936 trials

Advanced Non-Small Cell Lung Cancer: New Immunotherapy Combinations

We are evaluating new combinations of immunotherapy for adults with untreated advanced non-small cell lung cancer. The goal is to see if these combinations are safe and more effective than standard treatment.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Mesothelioma: Pembrolizumab and Dendritic Cell Vaccine

We are studying a combination of pembrolizumab and a personalized vaccine for patients with advanced mesothelioma who have not responded to earlier treatments. The goal is to see if this approach can improve outcomes for these patients.

Mesothelioma>2 yearsSafety phase (I)Oncology

Advanced Malignancies: Testing DSB2455

We are assessing a new anti-cancer treatment, DSB2455, for patients with advanced malignancies. The goal is to understand how well it works when given alone.

Breast Cancer without Active Brain MetastasesProstate Cancer with Active Brain MetastasesOvarian Cancer without Active Brain Metastases>2 yearsSafety phase (I)Oncology

CDR404 for Solid Tumors

We are testing a new treatment called CDR404 in patients with specific solid tumors. The study aims to evaluate its safety and effectiveness in fighting cancer.

Solid Tumors>2 yearsSafety phase (I)Oncology

Myeloid Malignancies: BGB-11417 Study

We are testing a new drug, BGB-11417, in combination with azacitidine for patients with myeloid malignancies. The goal is to find the safest dose and see how well it works against the disease.

Myeloid MalignanciesSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Acute Vaginal Infection: BGY-1601-VT Tablet

We are studying a new vaginal tablet for women with acute vaginal infections to see if it works better than a placebo. The trial will help us understand its safety and effectiveness for conditions like Bacterial Vaginosis and Vulvovaginal Candidiasis.

Gynecological Conditions1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesGynecology and ObstetricsInfectious Diseases

Advanced Solid Tumors: AMG 355 Treatment Study

We are exploring a new treatment called AMG 355, both alone and with Pembrolizumab, for individuals with advanced solid tumors. This study aims to assess its safety and potential effectiveness.

Malignant Solid Tumor>2 yearsSafety phase (I)Oncology

B-Cell Cancer: INT2104 Infusions

We are investigating the safety of INT2104 infusions for adults with B-cell cancers that have returned after previous treatments. This study aims to understand how well this new treatment works in this patient group.

Refractory B-Cell Malignancies>2 yearsSafety phase (I)Oncology

Gastrointestinal Cancer: Aerosolized Nanoliposomal Irinotecan

We are testing a new aerosolized treatment for patients with peritoneal carcinomatosis from gastrointestinal cancer. This study aims to evaluate the safety and dosage of this innovative approach.

Advanced Peritoneal Metastases from GI CancerSafety phase (I)GastroenterologyOncology

Advanced Solid Tumors: TransCon IL-2 β/γ Treatment Study

We are investigating the safety and tolerability of TransCon IL-2 β/γ alone and with other cancer therapies for adults with advanced solid tumors. This study aims to find the best dose and understand how it works in combination with existing treatments.

Advanced Solid Tumor Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Parkinson's Disease: New Treatment Study

We are testing a new treatment in healthy volunteers and individuals with Parkinson's disease, including those with specific genetic mutations. This study aims to understand how the treatment works in different groups.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Mevrometostat for Relapsed/Refractory Cancers

We are testing Mevrometostat in patients with relapsed or refractory small cell lung cancer, castration-resistant prostate cancer, and follicular lymphoma. The goal is to see how well it works in these challenging cases.

Castration Resistant Prostate CancerSmall Cell Lung CancerFollicular Lymphoma>2 yearsSafety phase (I)HematologyOncology

Colorectal Cancer Diagnosis: FAPI Imaging Study

We are exploring whether a new imaging method can help diagnose the CSM4 subtype of colorectal cancer more accurately. This study aims to improve detection and treatment options for patients.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

Spinal Cord Injury: TZ-161 Treatment Study

We are testing a new treatment for adults with early acute spinal cord injury to see if it is safe and effective compared to standard care. The study will also evaluate its effects on pain and recovery time.

Early Acute Spinal Cord Injury1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesNeurology

Cancer Treatment: Immune Therapy with Ultrasound

We are exploring a new treatment combining immune checkpoint inhibition therapy with focused ultrasound for cancer patients. This study aims to determine if this combination enhances the effectiveness of cancer treatment.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Acute Myeloid Leukemia: CD19 CAR-T Cell Therapy

We are studying the safety of a new CAR-T cell treatment for patients with refractory acute myeloid leukemia. This trial aims to see how well the treatment works and how long the CAR-T cells last in the body.

Recurrent Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Fast-Acting Insulins and Their Post-Meal Effects in Type 1 Diabetes

We are studying how different fast-acting insulins affect blood sugar levels after meals in people with type 1 diabetes. This research may help identify the best insulin for managing glucose and reducing oxidative stress.

Type 1 Diabetes1-2 yearsSafety phase (I)No PlaceboStandard MedicinesDiabetologyEndocrinology

Indolent Non-Hodgkin's Lymphoma: EO2463 Cancer Vaccine

We are investigating a new cancer vaccine, EO2463, for patients with indolent Non-Hodgkin's Lymphoma. The trial aims to assess its safety and effectiveness alone and with other treatments.

Indolent Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: BEAM-302 Treatment Study

We are exploring a new treatment for adults with Alpha-1 Antitrypsin Deficiency-related lung or liver disease. The study aims to evaluate its safety and effectiveness in improving health outcomes.

Alpha-1 Antitrypsin Deficiency (AATD)>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyPulmonology

B-cell Non-Hodgkin Lymphoma: JNJ-88998377

We are testing a new treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. This study aims to find a safe dose and understand how the treatment works in humans.

Relapsed or Refractory B-cell Non-Hodgkin Lymphomas>2 yearsSafety phase (I)Oncology